Clinical trials: Germ Cell Tumour
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Vestibular Schwannoma
Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy
This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of…
- Trial name
- NCT07503613
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Akouos, Inc.
Prostate Cancer, Melanoma
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the…
- Conditions
- Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma
- Trial name
- NCT00818480
- Testing
- YM155
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Astellas Pharma Inc
Askin's Tumors, Desmoplastic Small Round Cell Tumors
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
Single-arm, open-label study of AMG 479 in up to 35 subjects with Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have progressed or recurred after at least one prior chemotherapy regimen.
- Conditions
- Askin's Tumors, Desmoplastic Small Round Cell Tumors, Estraosseous Ewing's Tumor, Ewing's Family Tumor
- Trial name
- NCT00563680
- Testing
- AMG 479
- Volunteers
- 38 people
- Sponsor
- NantCell, Inc.
Neuroendocrine Neoplasm, Neuroendocrine Carcinomas
Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine Neoplasms
This study will enroll patients with central lab confirmed NCAM (CD56 IHC) positive metastatic neuroendocrine neoplasms that have progressed after standard of care treatment.
- Conditions
- Neuroendocrine Neoplasm, Neuroendocrine Carcinomas, Neuroendocrine Tumors
- Trial name
- NCT07684170
- Testing
- CTX-471
- Volunteers
- 58 people
- Sponsor
- Compass Therapeutics
Cutaneous Melanoma, Non-small Cell Lung Cancer
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms
- Trial name
- NCT05571839
- Testing
- PF-08046049
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 41 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Glioma
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
The main purpose of this study is to assess the effect of a two-week pre-surgery treatment with low-dose temozolomide (TMZ) on brain tumor methylguanine-DNA (deoxyribonucleic acid) methyltransferase (MGMT) activity in patients…
- Trial name
- NCT00424554
- Testing
- temozolomide
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma
IVAC MUTANOME Phase I Clinical Trial
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002…
- Trial name
- NCT02035956
- Testing
- IVAC MUTANOME, RBL001/RBL002
- Where
- 3 sites in Austria, Germany
- Volunteers
- 15 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Recurrent Malignant Glioma, Brain Glioblastoma
Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma
This is a phase II open-label study investigating the efficacy, safety and pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with recurrent glioblastoma(GBM).
- Trial name
- NCT04388475
- Testing
- OKN-007, Temozolomide (TMZ)
- Where
- 13 sites in United States
- Volunteers
- 57 people
- Sponsor
- Oblato, Inc.
Oncology, DIPG
xPedite: A Study to Expedite DIPG and DMG Research
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external…
- Conditions
- Oncology, DIPG, DMG
- Trial name
- NCT06140719
- Where
- United States
- Sponsor
- xCures
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Melanoma
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
The purpose of this study is to determine the survival rate after 1 year of treatment with ipilimumab plus dacarbazine in patients with previously untreated Stage III (unresectable) or Stage IV melanoma.
- Trial name
- NCT01681212
- Testing
- Ipilimumab, Dacarbazine
- Where
- 6 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer
- Trial name
- NCT03906331
- Testing
- Selpercatinib
- Where
- 64 sites in United States, Australia and 11 more
- Sponsor
- Eli Lilly and Company
Melanoma
A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
The purpose of this research study is to find out whether JX-594 (Pexa-Vec) is safe and effective for treating surgically unresectable malignant melanoma.
- Trial name
- NCT00429312
- Testing
- JX-594
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Jennerex Biotherapeutics
Melanoma Stage III, Melanoma Stage IV
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block…
- Trial name
- NCT03161431
- Testing
- SX-682, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 77 people
- Sponsor
- Syntrix Biosystems, Inc.
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Advanced Solid Tumors, Advanced Recurrent Ovarian Tumors
A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors
To determine the maximum tolerated dose or optimal biological dose, and the safety profile of MEDI3617 when given as a single-agent or in combination with other chemotherapeutic agents in subjects with advanced solid malignancies…
- Trial name
- NCT01248949
- Testing
- MEDI3617, Bevacizumab, Paclitaxel
- Where
- 10 sites in United States
- Volunteers
- 162 people
- Sponsor
- MedImmune LLC
Unresectable Stage III, Stage IV Melanoma
An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma
The purpose of this study is to assess the objective response rate of lenvatinib in previously treated participants with American Joint Committee on Cancer (AJCC) unresectable Stage III or Stage IV melanoma and disease…
- Trial name
- NCT01136967
- Testing
- Lenvatinib
- Where
- 95 sites in United States, Australia and 2 more
- Volunteers
- 182 people
- Sponsor
- Eisai Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.